PharmaResearch's Q1 2026 results, announced May 8, look flawless at first glance. Revenue of KRW 146.1 billion, operating profit of KRW 57.3 billion, net income of KRW 48.7 billion — all three are quarterly records. Year-over-year, revenue rose 25%, operating profit rose 28%, and net income rose 35%. Yet the stock failed to gain traction after the release. The reason is simple: the absolute figures were record highs, but they still fell short of the bar the market had already set — the consensus. And what created that gap was the company's flagship business, the "Rejuran" skin booster medical device division. What actually filled the gap was the comparatively under-the-radar Rejuran Cosmetics line, and within it, duty-free and foreign-shopper spending in particular.
What Happened — Confirmed Q1 2026 Results
PharmaResearch's Q1 2026 results by business segment were as follows.
| Segment | Revenue | Domestic | Export |
|---|
| Medical Devices (skin boosters, etc.) | KRW 79.5 billion | KRW 58.4 billion | KRW 21.1 billion |
| Cosmetics (Rejuran Cosmetics) | KRW 42.2 billion | KRW 15.3 billion | KRW 26.9 billion |
| Pharmaceuticals | KRW 21.4 billion | KRW 11.2 billion | KRW 10.2 billion |
| Company-wide total | KRW 146.1 billion | | |
Operating profit came to KRW 57.3 billion (operating margin 39.2%), and net income was KRW 48.7 billion. Yet brokerage consensus had called for revenue of KRW 150.7 billion and operating profit of KRW 60.3 billion — meaning the actual results fell about 3% short on revenue and about 5% short on operating profit relative to that bar. "Record-high results" and "a miss versus market forecasts" can both be true at once precisely because the market had been pricing in even bigger growth.
Core Insight 1 — The Miss Originated at Rejuran's Home Turf: Medical Devices
What ate into the forecast wasn't cosmetics or pharmaceuticals — it was the company's core cash cow, the medical device division. Domestic medical device revenue of KRW 58.4 billion fell short of even the low end of the market's expected range (KRW 58.8 billion–60.3 billion), and exports of KRW 21.1 billion clearly missed forecasts (KRW 23.8 billion–24.0 billion). Exports in particular fell 10.2% quarter-over-quarter.
Analysts point to two causes. One is seasonality: "Q1 is the off-season for foreign dermatology spending," with inbound tourists' dermatology-related spending falling by as much as KRW 110 billion compared to the previous quarter. This isn't a figure specific to PharmaResearch alone — it reflects foreign tourists' overall dermatology spending in Korea. The other is structural: intensifying competition in the skin-booster market and downward pressure on unit prices, both of which took hold from the second half of 2025. This pressure isn't new — it's the same factor behind the 23% single-day stock plunge that followed the Q4 2025 earnings release on February 5 (revenue KRW 142.8 billion, operating profit KRW 51.8 billion, missing consensus by -8% and -20% respectively). In other words, this quarter hit an all-time high in absolute terms, but the very weakness (pricing pressure) that triggered the Q4 shock hasn't been fully resolved.
A Closer Look at Rejuran Cosmetics — Duty-Free Highlights
Cosmetics filled the gap left by medical devices. Rejuran Cosmetics revenue came to KRW 42.2 billion, up 51% year-over-year — the highest growth rate of any division — and its share of company-wide revenue jumped from 23.9% to 29%. Both domestic (KRW 15.3 billion, +43.3%) and export (KRW 26.9 billion, +55.8%) sales grew by double digits or more.
Here, duty-free's role needs to be addressed. But first, a caveat: PharmaResearch discloses cosmetics revenue only by domestic/export split and doesn't break out the duty-free channel separately. So a confirmed "duty-free revenue of X billion won" figure can't be verified from company disclosures alone. Still, industry sources believe most Rejuran Cosmetics revenue comes from two channels — drugstores (like Olive Young) and duty-free — with duty-free accounting for a fairly sizable share. Indeed, Rejuran Cosmetics is carried at domestic duty-free stores including Shilla Duty Free's Yongsan I'Park Mall location.
The company itself cited "a surge in foreign shopping amid the combined effect of exchange rates and the holiday calendar" as the driver behind this quarter's 43.3% domestic cosmetics growth. In other words, much of the growth in domestic cosmetics sales came not from Korean consumers, but from the wallets of foreign tourists visiting Korea — suggesting duty-free and foreigner-focused stores were the key conduit for this growth. Overseas distribution expansion added to this. Rejuran Cosmetics soft-launched on Sephora's U.S. online store on March 1, 2026, followed by a phased rollout starting March 16 to roughly 380 Sephora physical stores across the U.S. In China, it's also listed on Taobao, the country's largest open marketplace. With simultaneous entry into domestic duty-free and overseas specialty retail, Rejuran Cosmetics is building a structure that generates revenue from both foreign visitors to Korea and local consumers overseas at the same time.
Core Insight 2 — The Same Foreign Tourists Moved in Opposite Directions Across Two Channels
The most interesting part of this quarter's results lies elsewhere. PharmaResearch's business connects to foreign tourists in two distinct ways — one is medical tourism demand for Rejuran treatments at dermatology clinics (tied to domestic medical device revenue), and the other is retail demand for Rejuran Cosmetics bought at duty-free stores and counters (tied to domestic cosmetics revenue). This quarter, the two channels moved in opposite directions. Foreign dermatology spending plunged KRW 110 billion quarter-over-quarter, while foreign shopping for Rejuran Cosmetics surged, lifting domestic cosmetics revenue by 43.3%.
In other words, the same foreign tourists got fewer treatments and did more shopping in the same quarter. This connects with the broader shift RIT has previously tracked in its K-beauty field series — a shift in weight from group-tour, treatment-centered spending toward individual-tourism, retail-centered spending. But this case shows something more than that. Within a single company, the same customer can send opposite signals depending on which channel you're standing in. In practice, a divergence like this is easy to miss inside a single company's report — at the exact moment the medical device division alone would have you worried that "foreign demand has slumped," the cosmetics division was celebrating that "foreign shopping surged."
Business Impact — European Expansion and the Q2 Outlook
On the medical device export side, Europe has emerged as a new variable. Shipments to Europe through French distributor VIVACY were partially reflected in Q1, bringing first-half European exports to about KRW 6.0 billion. If a similar volume of shipments continues in the second half, full-year European exports could reach roughly KRW 12.0 billion, potentially exceeding the original full-year guidance.
Q2 2026 results had not yet been announced as of this writing. The market expects revenue of KRW 162.4 billion and operating profit of KRW 65.0 billion, an improvement over Q1 — though these are forecasts, not confirmed figures. Some note that given the high base from the same period last year (Q2 2025 results), the growth rate itself could slow compared to Q1. Ultimately, the key question is whether the medical device division shows a combined domestic and export recovery as it enters its seasonal peak (Q2), or whether cosmetics keeps filling the gap instead. The fact that the same foreign tourists closed their wallets at the dermatology clinic while opening them at the store is a contrast that will remain a useful lens for reading next quarter's results too.
✦RIT's Insights
What's most worth watching in these results is the directional problem hiding behind the "record high" headline. Seeing revenue and profit hit all-time highs alone gives the impression the company is doing well across the board. But miss the fact that the two engines behind that record — medical devices and cosmetics — were pointed in opposite directions, and you misread where this company is actually headed. Medical devices sounded an alarm by missing the market's forecast; cosmetics drowned out that alarm by beating it by a wide margin. This is exactly what stands out most to RIT in these results — anyone on the investment or analyst side needs to re-internalize the principle that "record-high results" and "a miss versus market forecasts" can perfectly well be true at the same time. Rather than looking only at the headline growth rate, checking whether there was a miss relative to market expectations, and which specific division drove it, is what actually shows where the company is headed.
In RIT's view, the more interesting point is that the same foreign tourists showed two different faces within one company. Dermatology treatment demand and cosmetics purchase demand may look, at first glance, like two sides of the same customer base, but they actually run on entirely different decision-making structures. A treatment is high-involvement spending that requires booking, cost, and recovery time, while duty-free shopping is closer to low-involvement, impulse spending during a travel itinerary. That means macro variables like exchange rates or peak travel season can affect the two kinds of spending at different speeds and in different directions. For anyone managing a business portfolio, the lesson here is that demand can move in opposite directions across channels even when targeting the same customer base, as with medical tourism (treatment) versus retail (shopping) — and avoiding the mistake of reading weakness in one channel as a broader customer exodus requires tracking channel-level metrics separately as a matter of habit.
How PharmaResearch synchronizes these two engines going forward, and whether the company is ever willing to directly disclose the contribution of its duty-free/retail channel, are reasons to keep watching this company. Anyone handling duty-free or retail MD has a useful workaround here — even for a company like this one that doesn't disclose duty-free separately, cross-referencing domestic revenue growth rates against management commentary on "foreign shopping" can offer an indirect read on the duty-free channel's real contribution. And for anyone thinking about brand expansion, this case also shows that a dual-distribution strategy — simultaneous entry into domestic duty-free and overseas specialty retail like Sephora, targeting inbound tourists and local consumers at the same time — can offset the seasonal swings of any single channel.
Sources
- PharmaResearch's Q1 revenue hits KRW 146.1bn, operating profit KRW 57.3bn — a quarterly record (Hankyung, 2026-05-08, Q1 2026 segment results)
- "Rejuran boom" PharmaResearch's stock falls 23% in a single day — why? (Nate News, 2026-02-07, Q4 2025 results, the consensus miss, and the stock-drop background)
- PharmaResearch's "Rejuran Cosmetic" enters Sephora's online and offline channels in the US (Etoday, 2026-03, the Sephora rollout schedule and store count)
- DART electronic disclosure system (dart.fss.or.kr) — PharmaResearch Co., Ltd. quarterly reports (cited by name where a specific filing URL could not be pinpointed)
